As president, I'm also taking on the gigantic health insurance companies that have gotten rich on billions of dollars of government subsidies. And I want the money to go directly to the people. I want the money to be paid directly to the people so that they can buy their own health insurance which will give far better benefits at much lower cost.By the way, what I told you about buying the drugs at this massive uh dollar discount, it's like from where it is, that's going to have a huge impact on the cost of ...

Digital Assets - Digital assets companies have made progress with the passage of a light-touch regulatory law for dollar-pegged stablecoins, facilitating broader use of the technology in everyday finance [1] - The crypto industry is pushing for a comprehensive rewrite of securities and commodities laws to establish favorable regulations for cryptoassets, supported by a $263 million campaign war chest amassed in super-PACs [1] Energy Sector - Energy companies have secured a tax break exceeding $1 billion for oil and gas producers as part of the Trump tax package, allowing deductions for certain drilling costs under a 15% corporate alternative minimum tax [2] Private Equity - Congressional Republicans resisted President Trump's initial demands to raise taxes on carried interest, preserving a tax break favored by private equity, while also achieving an expanded interest expensing tax break [3] Technology Sector - America's most valuable company, Nvidia, successfully countered efforts by Republican China hawks to prioritize US companies for its products, aided by CEO Jensen Huang's lobbying in Congress and the White House [4] Healthcare and Renewable Energy - The healthcare sector, along with renewable energy companies, faced legislative challenges, while chipmakers and drug companies managed to avoid significant congressional interventions [5] Tax Cuts and Corporate Benefits - The Republican-controlled Congress has been favorable to corporate America, highlighted by a $4 trillion tax cut package that extended and added generous breaks for businesses [6] - Drug companies largely blocked legislative efforts aimed at controlling their prices, despite Trump's rhetoric on requiring price cuts [6] Defense Industry - The defense industry successfully increased the Pentagon budget by $150 billion as part of Trump's tax and spending package, with notable beneficiaries including Anduril Industries, Palantir Technologies, and Boeing [9] Financial Sector - The passage of stablecoin legislation poses a threat to the banking sector's dominance in the payments system, although bankers managed to block legislation aimed at reducing credit card swipe fees [16] Casinos - Professional gamblers are now limited to deducting only 90% of their losses against winnings under the new tax bill, prompting major casino companies to seek repeal of this provision [17] Airlines - Airlines incurred significant losses during the longest government shutdown, with Delta Air Lines estimating a $200 million revenue hit [18] Importers - Retailers and importers affected by Trump's tariffs received minimal support from lawmakers, as Republicans largely refrained from intervening in trade issues [20]

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. UnitedHealth has pledged to make a range of improvements in response to the first outside reviews of its business practices as the healthcare behemoth works to improve waning consumer trust. The independent analyses, completed by FTI Consulting and the Analysis Group in November and released on Friday, didn’t find a smoking gun that UnitedHealth is leveraging ...

Group 1 - UnitedHealth Group Incorporated (NYSE:UNH) is undergoing operational changes due to audits of its health services and pharmacy benefit units, focusing on increased automation and standardization [1] - CEO Stephen Hemsley announced a comprehensive examination of managed care practices and pharmacy benefits, with 23 action plans already in progress, over half of which will be finalized by the end of this year [2][3] - UnitedHealth Group will share the results of the HouseCalls visit review in fiscal Q1 2026 [3] Group 2 - UnitedHealth Group reported that Optum Rx is modernizing pharmacy reimbursement methods, partnering with three additional Pharmacy Services Administration Organizations (PSAOs) to implement cost-based contracts for over 17,000 community pharmacies [4] - The initiative aims to better support community pharmacies, with 100% of community and independent pharmacies in the Optum Rx network transitioning to the new reimbursement model [5] - UnitedHealth Group operates through various segments, including OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare, providing healthcare coverage, data consultancy, and software services [5]

On the flip side, Steve Conners, president of Conners Wealth Management, said he’s looking at the large cap healthcare sector, particularly at pharmaceuticals and biotechnology. “The artificial intelligence theme has left them mostly ignored. Valuations are still attractive at current levels,” he said. He is avoiding health insurers in the broader healthcare space, however, saying they remain under too much pressure with the focus on rising health insurance premiums. “I’m not really interested in being the ...

Core Points - US President Donald Trump announced agreements with nine pharmaceutical companies aimed at lowering drug prices for Americans in exchange for a three-year delay on threatened tariffs [1][2] - A total of 14 out of 17 targeted drugmakers have agreed to lower prices for the Medicaid program, sell discounted drugs directly to consumers, and align US drug prices with those abroad [2][3] - Companies such as Roche, Novartis, Bristol-Myers Squibb, Gilead, and others have negotiated agreements, while AbbVie, Johnson & Johnson, and Regeneron are still in talks [3][4] Drug Pricing Agreements - Bristol-Myers Squibb will provide its blood-thinner Eliquis for free to the Medicaid program, and Gilead will reduce the price of its hepatitis C drug Epclusa to under $2,500 [7] - Many medications highlighted by the administration are already available at discounted prices through patient assistance programs or have cheaper generic alternatives [8] Insurance Industry Impact - Trump's announcements led to declines in health insurance stocks, including UnitedHealth Group, Elevance Health, and CVS Health [10] - The insurance industry trade group AHIP stated that premiums reflect medical care costs and welcomed discussions on cost reduction [10][11] Manufacturing and Supply Chain - Companies like Merck, Bristol-Myers, and GSK agreed to donate six months' worth of raw drug materials to a national stockpile and commit to manufacturing finished medicines in emergencies [12] Political and Regulatory Context - Democrats are seeking more transparency regarding the potential savings from these tariff relief deals, as the agreements remain confidential [13]

Core Viewpoint - The article discusses the 12 most widely held stocks by hedge funds in 2025, highlighting market expectations and specific company developments that may influence investment decisions. Group 1: Market Expectations - Lori Calvasina from RBC Capital Markets anticipates 2026 to be a good year for markets, despite recent drawdowns and ongoing market angst [2] - There is a notable upward revision in earnings expectations, although not as strong as previous summer figures, indicating some healthy movements in the market [2] Group 2: Hedge Fund Stock Holdings - The article lists the top 12 stocks held by hedge funds as of Q3 2025, emphasizing the importance of these stocks for potential market outperformance [6][7] - UnitedHealth Group Incorporated (NYSE:UNH) is highlighted as one of the most widely held stocks, with 140 hedge fund holders [8] - Uber Technologies, Inc. (NYSE:UBER) is also among the top stocks, with 143 hedge fund holders, and has received mixed analyst ratings recently [14] Group 3: Company Developments - UnitedHealth Group is undergoing operational changes, including increased automation and standardization, following audits of its health services and pharmacy benefit units [9][10] - The CEO of UnitedHealth Group has committed to a comprehensive examination of key policies and processes, with several action plans already completed [10][11] - Uber Technologies has seen a price target adjustment from analysts, with one maintaining a Buy rating and another reducing the target, reflecting differing views on the company's strategic positioning in the autonomous vehicle market [15][16]

Group 1: Drug Price Cuts and Pharmaceutical Stocks - President Trump announced significant drug price cuts in collaboration with nine major pharmaceutical companies, aiming to align U.S. drug costs with those in other developed nations [2] - Despite the announcement of price cuts, shares of involved drugmakers like GSK, Merck, Amgen, Novartis, Sanofi, and Roche rose by approximately 1% to 3%, as the deals removed the immediate threat of punitive tariffs for three years [3] - Analysts noted that the deals serve more as a public relations strategy rather than a substantial change in company economics, with Medicaid already benefiting from significant discounts [4] Group 2: Market Reactions to Health Insurers - Major health insurers such as Cigna, CVS Health, Elevance Health, and UnitedHealth Group experienced an initial dip of about 1% following Trump's comments but quickly recovered, indicating a market accustomed to Trump's policy announcements [5] Group 3: Merger of Trump Media & Technology Group and TAE Technologies - Trump Media & Technology Group announced a merger with TAE Technologies, valuing the combined entity at $6 billion, which led to a 42% surge in DJT shares, closing at $14.86 [7] - The merger has drawn mixed reactions, with some analysts viewing it as a significant move towards creating a public nuclear fusion company, while others criticized it as a questionable venture [9] Group 4: Tariff Threats and Market Volatility - Throughout 2025, Trump's threats and impositions of tariffs, particularly against China, have caused significant market volatility, including a $5 trillion market wipeout following an April tariff announcement [11] - The S&P 500 and Nasdaq Composite experienced substantial declines during tariff threats, but the market has shown resilience, often recovering to new highs [12] Group 5: Overall Market Environment - As 2025 concludes, the financial markets continue to be influenced by Trump's unpredictable policies, creating a landscape where traditional analysis is often overshadowed by political developments [13]

Core Insights - President Trump announced a set of drug-pricing agreements with nine major pharmaceutical companies, aiming to align U.S. medicine costs with those in Europe [1][2] - The initiative includes a new direct-to-consumer portal, TrumpRx.gov, allowing patients to purchase certain medicines directly from manufacturers [2][4] Group 1: Agreements and Participants - The agreements involve 14 out of 17 drugmakers that Trump previously urged to lower prices, including Amgen, GSK, and Merck [2][3] - Drug companies are motivated to negotiate to avoid potential regulatory measures that could impact their profits [3] Group 2: TrumpRx.gov Functionality - TrumpRx.gov will serve as a central directory for patients to access selected medicines directly from manufacturers' websites [4] - The portal is expected to be fully operational by January, following a promotional launch [4] Group 3: Pricing Details - Highlighted medicines include Amgen's Repatha at $239/month, GSK's Advair Diskus at $89/month, and Merck's Januvia at $100/month [6] - Gilead's Epclusa will be priced at $2,492/month, despite lower costs for insured patients [6] Group 4: Impact on Medicaid and Medicare - Companies committed to launching new medicines in the U.S. at prices comparable to those in other wealthy countries [8] - Medicaid programs are legally entitled to the lowest drug prices, with Bristol Myers Squibb offering Eliquis free to Medicaid [9] Group 5: Industry Response and Future Outlook - Health policy experts express skepticism about the agreements' impact on overall drug prices for most Americans [10] - The agreements do not impose mandatory price controls and leave many brand-name drug costs unchanged [15] - Ongoing discussions with additional manufacturers like AbbVie and Johnson & Johnson may lead to further agreements [14]

Group 1: United Health - United Health is the worst performing stock in the Dow, down over 34% in 2025 due to rising medical costs and regulatory scrutiny over its Medicare Advantage business [56][57]. - The company faced challenges with medical cost management and leadership changes, which negatively impacted investor sentiment [60][61]. - Despite the difficulties, there are signs of a potential turnaround, with management guiding for EPS growth in 2026 [66][68]. Group 2: Salesforce - Salesforce shares are down more than 22% in 2025, facing concerns about AI's impact on its software and pressure from activist investors [81]. - The company has struggled to monetize AI effectively, leading to skepticism about its future growth prospects [82][84]. - Analysts suggest that Salesforce needs to improve its enterprise sales and product offerings to regain investor confidence [82][90]. Group 3: Proctor and Gamble - Proctor and Gamble is down about 14% this year, attributed to a deceleration in organic sales growth and cautious consumer spending [41][42]. - The company has seen a shift in consumer behavior, with a decline in premium product sales impacting overall performance [43][44]. - There is optimism for 2026, as the company may benefit from a normalization of sales growth trends and improved consumer sentiment [45][50]. Group 4: Nike - Nike is down about 11% this year, struggling with inventory issues and a prolonged turnaround process [8][9]. - The company has faced challenges in its lifestyle segment, losing market share due to changing consumer preferences [22][24]. - Analysts believe that Nike needs to demonstrate topline growth and regain consumer interest to improve its stock performance [21][23]. Group 5: Honeywell - Honeywell shares are down more than 6% in 2025, impacted by structural changes and a lack of exposure to high-growth sectors like AI [100][103]. - The company is undergoing a transformation to unlock value through spin-offs, but execution will be key to realizing this potential [101][104]. - Analysts expect Honeywell's aerospace business to show improvement in margins and growth in 2026 as contracts are reset [110][113].